Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Starting soon · Phase 1/Phase 2

Conditions studied: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

In brief

Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Key facts

Study ID

NCT07435038

Run by

Betta Pharmaceuticals Co., Ltd.

People needed

120

Starts

2026-02-12

Expected to finish

2029-10-28

Last updated by the study team

2026-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.
• Have received prior standard therapy appropriate for tumor type and stage.
• Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function.

You may not qualify if…

• Primary central nervous system (CNS) tumors active and untreated brain metastases.
• Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication.
• History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.